Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors (NCT05280314)
Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Who can join: Review the eligibility criteria below.
Location: Yale — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Yale — New Haven, Connecticut
- Dana Farber Cancer Institute — Boston, Massachusetts
- Massey Cancer Center — Richmond, Virginia
- Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital — Sydney, New South Wales
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Aarhus University Hospital — Aarhus,
- Copenhagen University Hospital Herlev — Copenhagen,
- CHRU Lille — Lille,
- Hôpital Ambroise-Paré — Paris,
- Institut Gustave Roussy — Paris,
- Universitätsklinikum Essen & Research Alliance Ruhr — Essen,
- Universität Heidelberg, Medizinische Fakultät — Heidelberg,
- Hospital Universitario Quirón Dexeus — Barcelona,
- Hospital Universitario Ramón y Cajal — Madrid,
- Hospital Clínico Universitario de Valencia -INCLIVA — Valencia,
📞 Contact the Study Coordinator
Phone: (267) 252-7296
Email: dmd@iobiotech.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.